RVOT3V79
RVOT3V79
RVOT3V79
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
208 Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman<br />
PD, et al. Effects of long-term atomoxetine treatment for young children<br />
with attention-deficit/hyperactivity disorder. J Am Acad Child<br />
Adolesc Psychiatry. 2006 Aug;45(8):919-27.<br />
209 Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers<br />
AK, et al. Long-term atomoxetine treatment in adolescents with<br />
attention-deficit/hyperactivity disorder. J Pediatr. 2006 Jul;149(1):<br />
112-9.<br />
210 Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman<br />
HM, et al. Treatment of attention-deficit/hyperactivity disorder: overview<br />
of the evidence. Pediatrics. 2005 Jun;115(6):e749-e757.<br />
211 FDA Alert [09/05]: Suicidal thinking in children and adolescents. U S<br />
Food and Drug Administration 2005 December 29. Disponible en: URL:<br />
http://www.fda.gov/cder/drug/infopage/atomoxetine/default.htm.<br />
212 Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular<br />
monitoring of children and adolescents with heart disease<br />
receiving stimulant drugs: a scientific statement from the American<br />
Heart Association Council on Cardiovascular Disease in the Young<br />
Congenital Cardiac Defects Committee and the Council on Cardiovascular<br />
Nursing. Circulation. 2008 May 6;117(18):2407-23.<br />
213 Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, et al. Cardiovascular<br />
effects of atomoxetine in children, adolescents, and adults.<br />
Drug Saf. 2003;26(10):729-40.<br />
214 Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and<br />
stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics.<br />
2008 Aug;122(2):451-3.<br />
215 Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL,<br />
Feldman PD, et al. Transition from methylphenidate or amphetamine<br />
to atomoxetine in children and adolescents with attention-deficit/hyperactivity<br />
disorder—a preliminary tolerability and efficacy study. Clin<br />
Ther. 2007 Jun;29(6):1168-77.<br />
216 Weiss MD, Virani A, Wasdell M, Faulkner L, Rea K. Atomoxetine in<br />
clinical practice. Future Neurology. 2006;1:249-58.<br />
217 Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen<br />
SJ. Long-term stimulant medication treatment of attentiondeficit/hyperactivity<br />
disorder: results from a population-based study. J<br />
Dev Behav Pediatr. 2006 Feb;27(1):1-10.<br />
218 Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl<br />
PL, et al. A dose-response study of OROS methylphenidate in children<br />
with attention-defi cit/hyperactivity disorder. Pediatrics. 2003<br />
Nov;112(5):e404.<br />
219 Smith BH, Pelham WE, Evans S, Gnagy E, Molina B, Bukstein O, et<br />
188 GuíaS DE PráCtICa CLíNICa EN EL SNS
Change language